GRI BIO, Inc. Files 8-K
Ticker: GRI · Form: 8-K · Filed: Oct 24, 2024 · CIK: 1824293
Sentiment: neutral
Topics: 8-K, corporate-filing, financials
TL;DR
GRI BIO (formerly Vallon Pharma) filed an 8-K on 10/24/24. Standard update.
AI Summary
GRI BIO, Inc. filed an 8-K on October 24, 2024, reporting other events and financial statements. The company, formerly known as Vallon Pharmaceuticals, Inc., is incorporated in Delaware and headquartered in La Jolla, California.
Why It Matters
This filing indicates GRI BIO, Inc. is providing updates on its corporate activities and financial status to the SEC.
Risk Assessment
Risk Level: low — This is a routine 8-K filing for corporate updates and financial statements, not indicating any specific negative events.
Key Numbers
- 001-40034 — SEC File Number (Identifies the company's filing history with the SEC.)
- 82-4369909 — IRS Employer Identification No. (Company's tax identification number.)
Key Players & Entities
- GRI BIO, Inc. (company) — Registrant
- Vallon Pharmaceuticals, Inc. (company) — Former company name
- October 24, 2024 (date) — Date of report
- La Jolla, CA (location) — Principal executive offices
FAQ
What specific 'Other Events' are being reported by GRI BIO, Inc. in this 8-K?
The filing indicates 'Other Events' are being reported, but the specific details are not provided in the header information.
When did GRI BIO, Inc. change its name from Vallon Pharmaceuticals, Inc.?
The date of the name change from Vallon Pharmaceuticals, Inc. to GRI BIO, Inc. was September 10, 2020.
What is the primary business of GRI BIO, Inc. according to its SIC code?
GRI BIO, Inc. is classified under SIC code 2834, which pertains to Pharmaceutical Preparations.
Where are GRI BIO, Inc.'s principal executive offices located?
The principal executive offices of GRI BIO, Inc. are located at 2223 Avenida de la Playa, Suite 208, La Jolla, CA 92037.
What is the fiscal year end for GRI BIO, Inc.?
The fiscal year end for GRI BIO, Inc. is December 31st.
Filing Stats: 421 words · 2 min read · ~1 pages · Grade level 10.7 · Accepted 2024-10-24 08:35:47
Key Financial Figures
- $0.0001 — ch registered Common Stock, par value $0.0001 per share GRI The Nasdaq Capital Mark
Filing Documents
- val-20241024.htm (8-K) — 23KB
- ex991_pressreleasewarrantc.htm (EX-99.1) — 15KB
- image_0.jpg (GRAPHIC) — 37KB
- val-20241024_g1.jpg (GRAPHIC) — 16KB
- val-20241024_g2.jpg (GRAPHIC) — 2KB
- 0001824293-24-000143.txt ( ) — 258KB
- val-20241024.xsd (EX-101.SCH) — 2KB
- val-20241024_def.xml (EX-101.DEF) — 3KB
- val-20241024_lab.xml (EX-101.LAB) — 24KB
- val-20241024_pre.xml (EX-101.PRE) — 15KB
- val-20241024_htm.xml (XML) — 3KB
01 Other Events
Item 8.01 Other Events. On October 24, 2024, the Company issued a press release announcing certain fundraising activity since the beginning of 2024 and other matters, which has been filed as Exhibit 99.1 to this Current Report on Form 8-K.
01 Financial Statements and Exhibits
Item 9.01 Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release issued by GRI Bio, Inc., dated October 24, 2024. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document). .
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: October 24, 2024 GRI Bio, Inc. By: /s/ Leanne Kelly Leanne Kelly Chief Financial Officer